Dr. Ajay Bansal
Claim this profileUniversity of Kansas Cancer Center
Studies Barrett's Esophagus
Studies Nonpolyposis Colorectal Cancer
5 reported clinical trials
7 drugs studied
Area of expertise
1Barrett's Esophagus
2Nonpolyposis Colorectal Cancer
MSH2 positive
MSH6 positive
MLH1 positive
Affiliated Hospitals
Clinical Trials Ajay Bansal is currently running
Obeticholic Acid
for Familial Adenomatous Polyposis
This phase IIa trial investigates if giving obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to a bile acid the body makes. It is fluid made and released by the liver. OCA binds to a receptor in the intestine that is believed to have a positive effect on preventing cancer development. OCA has been effective in treating primary biliary cholangitis (PBC), a liver disease, and is approved by the Food and Drug Administration (FDA) for use at a lower dose (10 mg). There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.
Recruiting0 awards Phase 2
Itraconazole
for Barrett's Esophagus
Recurrent Barrett's esophagus (BE) that occurs at the rate of 12.4%/year is the Achilles heel of the endoscopic treatment of high-risk BE. Over time, after eradication, BE ultimately recurs in as many as 30-50% of the patients putting them at risk for esophageal adenocarcinoma (EAC), thereby undoing the benefits of an effective initial therapy. Also, recurrences need retreatments that increase costs and complications including strictures and refractory ulcerations. A therapy to prevent recurrent BE does not currently exist. Itraconazole with its ability to inhibit important molecular pathways related to BE development could enhance the long-term effectiveness of endoscopic eradication of high-risk BE, thereby promoting a long-term cure
Recruiting1 award Phase 11 criteria
More about Ajay Bansal
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Ajay Bansal has experience with
- Obeticholic Acid
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
- Nogapendekin Alfa
- Placebo Administration
- Brush Test Of The Food Pipe
- Blood Test
Breakdown of trials Ajay Bansal has run
Barrett's Esophagus
Nonpolyposis Colorectal Cancer
Lynch Syndrome
Nasopharyngeal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ajay Bansal specialize in?
Ajay Bansal focuses on Barrett's Esophagus and Nonpolyposis Colorectal Cancer. In particular, much of their work with Barrett's Esophagus has involved treating patients, or patients who are undergoing treatment.
Is Ajay Bansal currently recruiting for clinical trials?
Yes, Ajay Bansal is currently recruiting for 4 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Ajay Bansal has studied deeply?
Yes, Ajay Bansal has studied treatments such as Obeticholic Acid, Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Nogapendekin Alfa.
What is the best way to schedule an appointment with Ajay Bansal?
Apply for one of the trials that Ajay Bansal is conducting.
What is the office address of Ajay Bansal?
The office of Ajay Bansal is located at: University of Kansas Cancer Center, Kansas City, Kansas 66160 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.